Healthcare Jan 04, 2022 09:09 AM (GMT+8) · EqualOcean
On January 4, 2022, cytosin lab therapeutics, which focuses on therapeutic technology and new drug research and development in the field of epigenetics, announced that it would recently complete a round of financing of nearly 200 million yuan. This round of financing is jointly led by zeyue capital and CDH VGC, followed by Kaitai capital, Dawu venture capital, SAIC Hengxu capital, and Haoyi capital as the exclusive financial adviser. It is reported that this round of financing will be used to accelerate the clinical development of multiple epigenetic targeted new drugs on Sailan pharmaceutical pipeline, and further build the epigenetic technology R & D platform of Sailan pharmaceutical epigenplus.